All News
According to the developers, the agency’s decision could accelerate and expand the registration pathway for JNJ-1900 in head and neck cancer.
Advertisement
Patients who received human milk oligosaccharide demonstrated preserved Shannon Diversity index compared with control.
PSA score at 24 weeks was the strongest predictor of survival, with a PSA concentration of 0.2 ng/mL or less predicting favorable outcomes in this group.
Previous data showed deep MRD-negative responses among patients with pretreated relapsed/refractory multiple myeloma who received cevostamab.
Jennifer A. Ligibel, MD, discussed the complex link between weight loss and cancer risk, exploring data from bariatric surgery and the emerging role of GLP-1s.
Advertisement
Philip Blumenfeld, MD, discussed the feasibility of radium 224 Alpha DaRT sources delivered via endoscopic ultrasound for patients with pancreatic cancer.
Patients with breast cancer who omitted sentinel lymph node surgery did not have an increased uptake in other forms of treatment like radiation therapy.
Data showing the bioequivalence of extended-release ruxolitinib tablets vs reference ruxolitinib supported the FDA approval across multiple indications.
Investment in early detection will drive further progress in increasing survival rates, according to Diane Simeone, MD.
135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Giuliano Borges,Rinat Yerushalmi,Marina N. Sharifi,Wassim McHayleh,J. Thaddeus Beck,Neelima Vidula, MD,Erika P. Hamilton, MD,Kristine J. Rinn,Joyce O’Shaughnessy, MD,Giuseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Giulia Tonini,Alessandro Paoli,Monica Binaschi,Li Cheng,Jennifer Crozier,Tomer Wasserman,Virginia Kaklamani, MD, DSc
TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study
ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce O’Shaughnessy, MD,Peter Schmid, MD,J. Thaddeus Beck,Michelino De Laurentiis,Giuseppe Curigliano,Hope S. Rugo, MD,Carlos H. Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Tomer Wasserman,Sara M. Tolaney, MD, MPH
Craig H. Moskowitz, MD, discussed the transition toward molecularly defined lymphoma care and the declining role of autologous stem cell transplantation.
Reducing vein-to-vein time and expanding manufacturing capacity represent ongoing challenges to optimizing the use of cellular therapy across indications.
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Cristina Saavedra,Vicente Carañana,Isabel Blancas,Carmen Hinojo-González,Alfonso Cortes-Salgado,Elena Galve,Rui Rui Zhang,Miguel Sampayo-Cordero,Daniel Alcalá-López,Juliana Carvalho-Santos,Olga Boix,Ana Garrido,Carlos H Barrios,Giuseppe Curigliano,Rupert Bartsch,Anne Claire Hardy Bessard,Tomer Wasserman,Javier Cortés, MD
138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer
ByErika P. Hamilton, MD,Giuseppe Curigliano,Miguel Martin, MD, PhD,Florence Lerebours,Junji Tsurutani,Marie-France Savard,Katarzyna J. Jerzak, MD, MSc, FRCPC,Xichun Hu,Luciana Carla Martins de Aquino Pimentel,Ciara C. O’Sullivan,Eriko Tokunaga,Alicia Okines,Chiun-Sheng Huang,William Jacot,Joohyuk Sohn,Eduardo Cronemberger Silva,Volkmar Mueller,Helene Viala,Shan Yang,Giovanna Granata,Qi Shen,Libero Santarpia,Veronique Dieras
New developments revealed regulatory milestones for bacterial therapeutic candidates and potential efficacy with vaccine-based approaches.
MinhTri Nguyen, MD, discusses why timely breast cancer care in rural areas is hindered by a "combination of burdens," including systemic policy issues.
Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.
The FDA issued a “safe to proceed” letter for an expanded access program for daraxonrasib in metastatic pancreatic ductal adenocarcinoma.
A panel of experts discussed the implications of the AQUILA trial and the FDA approval of subcutaneous daratumumab in high-risk smoldering multiple myeloma.
Data from the phase 3 VERITAC-2 trial support the FDA approval of vepdegestrant in this breast cancer population.
Post-surgical treatment, functional gains were improved among patients with breast cancer.
Updated findings from the TRUST-I and TRUST-II trials may reflect the importance of molecular testing in non–small cell lung cancer therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Toxicity From CD19, BCMA Therapy May Inform B-Cell Malignancy Surveillance
2
Nogapendekin Alfa Plus BCG Exhibits Efficacy Advantage in NMIBC In Situ
3
Sac-TMT Significantly Improves PFS/OS in Pretreated Endometrial Cancer
4
Subcutaneous Isatuximab May Optimize Multiple Myeloma Treatment Protocols
5